Protective CD8 Memory T Cell Responses to Mouse Melanoma Are Generated in the Absence of CD4 T Cell Help by Côté, Anik L. et al.
Protective CD8 Memory T Cell Responses to Mouse
Melanoma Are Generated in the Absence of CD4 T Cell
Help
Anik L. Co ˆte ´
., Katelyn T. Byrne
., Shannon M. Steinberg, Peisheng Zhang, Mary Jo Turk*
Dartmouth Medical School and the Norris Cotton Cancer Center, Lebanon, New Hampshire, United States of America
Abstract
Background: We have previously demonstrated that temporary depletion of CD4 T cells in mice with progressive B16
melanoma, followed by surgical tumor excision, induces protective memory CD8 T cell responses to melanoma/melanocyte
antigens. We also showed that persistence of these CD8 T cells is supported, in an antigen-dependent fashion, by
concurrent autoimmune melanocyte destruction. Herein we explore the requirement of CD4 T cell help in priming and
maintaining this protective CD8 T cell response to melanoma.
Methodology and Principal Findings: To induce melanoma/melanocyte antigen-specific CD8 T cells, B16 tumor bearing
mice were depleted of regulatory T cells (Treg) by either temporary, or long-term continuous treatment with anti-CD4 (mAb
clone GK1.5). Total depletion of CD4 T cells led to significant priming of IFN-c-producing CD8 T cell responses to TRP-2 and
gp100. Surprisingly, treatment with anti-CD25 (mAb clone PC61), to specifically deplete Treg cells while leaving help intact,
was ineffective at priming CD8 T cells. Thirty to sixty days after primary tumors were surgically excised, mice completely
lacking CD4 T cell help developed autoimmune vitiligo, and maintained antigen-specific memory CD8 T cell responses that
were highly effective at producing cytokines (IFN-c, TNF-a, and IL-2). Mice lacking total CD4 T cell help also mounted
protection against re-challenge with B16 melanoma sixty days after primary tumor excision.
Conclusions and Significance: This work establishes that CD4 T cell help is dispensable for the generation of protective
memory T cell responses to melanoma. Our findings support further use of CD4 T cell depletion therapy for inducing long-
lived immunity to cancer.
Citation: Co ˆte ´ AL, Byrne KT, Steinberg SM, Zhang P, Turk MJ (2011) Protective CD8 Memory T Cell Responses to Mouse Melanoma Are Generated in the Absence
of CD4 T Cell Help. PLoS ONE 6(10): e26491. doi:10.1371/journal.pone.0026491
Editor: George Kassiotis, MRC National Institute for Medical Research, United Kingdom
Received April 22, 2011; Accepted September 28, 2011; Published October 26, 2011
Copyright:  2011 Co ˆte ´ et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Support for this work was provided by the National Instititutes of Health (NIH)(grants R01 CA120777 and P20 RR 16437 COBRE to MJT), the Melanoma
Research Foundation (New Investigator Award to MJT), and the American Cancer Society (Institutional Award to MJT). ALC was supported by a Rosaline Borison
Fellowship (Dartmouth Medical School). KTB was supported by NIH T32 A107363, the Dartmouth Immunology Program, and the Joanna M. Nicolay Melanoma
Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mary.jo.turk@dartmouth.edu
. These authors contributed equally to this work.
Introduction
A major goal of tumor immunotherapy has been the generation
of long-lived, protective CD8 T cell memory. However, because
many tumor antigens are self-antigens, multiple hurdles must be
overcome before functional T cell memory to tumors can be
achieved in vivo [1]. Our previous work has demonstrated that
temporary depletion of CD4
+CD25
+ regulatory T cells (Treg)i n
melanoma tumor-bearing mice drives the priming of melanoma/
melanocyte antigen-specific CD8 T cells that develop into
protective memory following curative excision of the primary
tumor [2,3]. We more recently showed that these CD8 T cells are
maintained in a functional state, as long as 600 days following
priming, by melanocyte antigen provided in the context of
autoimmune vitiligo [4]. Therefore they represent a non-classical
type of antigen-dependent T cell memory [4]. In these studies,
regulatory T cells were depleted using an antibody to CD4 (mAb
clone GK1.5). This is a potent strategy for eliminating immuno-
suppressive natural CD4
+ Treg cells, precursors of induced CD4
+
Tregs cells (e.g. IL-35 producing T cells [5]), and suppressive IL-4
producing CD4 T cells [6], although long-term treatment with
anti-CD4 could also impair CD8 T cell memory by the
elimination of T cell help.
CD4 T cell help has been shown to be a critical component for
generating functional CD8 T cell memory against pathogens [7,8].
However its role in generating functional memory to tumors is less
well understood. In acute infectious disease models, CD4 T cell
help has been shown to be necessary during the priming phase
[9,10], the maintenance phase [10,11], and/or the recall phase
[11,12] of the response, but is completely dispensable in other
cases [10]. Furthermore, CD4 T cell help has been shown to be
required in persistent infection models, where CD8 T cells receive
long-term antigen exposure [13]. In models that require T cell
help, the absence of CD4 T cells leads to progressive decline in
CD8 T cell population size, as well as a loss in T cell effector
function and recall capacity [14,15]. With regards to tumor-
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improve primary CD8 T cell responses [16], prevent CD8 T cell
tolerance by improving dendritic cell function [17], and support
secondary recall responses upon viral vaccine boosting [18].
However, our own studies have shown that memory CD8 T cell
responses to melanoma/melanocyte differentiation antigens TRP-
2 and gp100 can be generated despite early transient ablation of
CD4 helper T cells. In these studies, CD4 helper T cells were
present early during priming, and again after surgical tumor
excision [2,3], although the importance of CD4 T cell help for the
development and maintenance of functional memory to tumor/
self antigens has remained unclear.
The goal of the present studies was to investigate whether CD4
T cell help is required for the generation of protective CD8 T cell
memory to melanoma. These studies focus on functional memory
that is maintained following surgical excision of a primary tumor
[3,4], as a model of protection against tumor recurrence and
metastasis. We report that complete depletion of CD4 T cells
throughout the entire priming and maintenance phases of the
memory response still promotes T cell priming, the generation of
autoimmune vitiligo, the development of antigen-specific CD8 T
cell memory, and the maintenance of long-lived tumor protection.
These studies demonstrate the dispensable nature of T cell help for
the generation of CD8 T cell memory to tumor/self-antigens, and
establish CD4 T cell depletion as a potent strategy for inducing
lasting immunity to cancer.
Results
CD4 T cell help is not required for the priming of antigen-
specific CD8 T cell responses to B16 melanoma
We have previously shown that treatment of mice with anti-
CD4 (mAb clone GK1.5) on days 4 and 10 of B16 melanoma
tumor growth induces priming of a protective CD8 T cell response
against melanoma differentiation antigens, as a result of
CD4
+CD25
+ Treg depletion [2]. Anti-CD4 treatment did not
impair primary tumor growth, although it induced concomitant
immunity against re-challenge with melanoma tumors [2]. Non-
melanoma tumors grew normally in these mice, demonstrating
that tumor-rejection antigens were shared melanoma antigens [2].
Notably, even total depletion of CD4 T cells, beginning 2 days
prior to tumor inoculation, induced concomitant tumor immunity
in these mice [2]. However, the influence of early T cell help on
the priming of melanoma antigen-specific CD8 T cell responses
was not assessed. To specifically address this, tumor-bearing mice
were treated with anti-CD4 either on days 4 and 10 (early help), or
days 22, 4, and 10 (no help), relative to primary tumor inoculation
(Figure 1A). Endogenous primary CD8 T cell responses were
assessed by IFN-c ELISPOT on day 12. As we have previously
published [2,3], CD8 T cell responses to TRP-2 were not naturally
primed in B16 tumor-bearing mice that did not receive anti-CD4
treatment (Figure 1B). However, CD4 depletion on days 4 and 10
of tumor growth induced significant priming of CD8 T cells
specific for TRP-2180–188, as compared with an irrelevant peptide
control (Figure 1B). Notably, completely eliminating help by CD4
depletion on days 22, 4, and 10, did not impair this CD8 T cell
response (Figure 1B). In fact, responses to TRP-2 were significantly
greater in hosts that received total CD4 depletion (Figure 1B),
which could reflect earlier depletion of CD4
+CD25
+ Treg cells in
these mice. Because these endogenous T cell responses were small,
we also tracked antigen-specific T cell priming by adoptively
transferring 10
4 naı ¨ve, congenically (Thy1.1) marked, gp100-
specific pmel T cells one day prior to tumor inoculation, as we
have previously described [3,4]. Again, priming of CD8 T cells
only occurred in tumor-bearing mice that were treated with anti-
CD4 (Figure 1C). In accordance with ELISPOT results, there was
no impairment in the priming of pmel cells with an antigen-
experienced CD44
hi phenotype in mice that had received no help
as compared to early help (Figure 1C). Thus, CD8 T cell responses
to TRP-2 and gp100 were generated despite the complete absence
of CD4 T cell help during priming.
In an attempt to distinguish whether improved CD8 T cell
priming could be achieved in the presence of T cell help, mice
were alternatively treated with anti-CD25 (mAb clone PC61) to
selectively deplete CD25
+ Treg cells, while preserving
CD25
2CD4
+ helper T cells. Anti-CD25 treatment was adminis-
tered once, beginning 4 days prior to primary tumor inoculation,
to avoid depletion of effector CD8 T cells, which can also express
CD25. Anti-CD25 treatment resulted in total elimination of CD25
expression on CD4 T cells, but only a ,50% reduction in the
Foxp3
+ CD4 T cell compartment (Figure 2A). Therefore, as
previously reported [19,20], PC61 treatment reduced, but did not
completely eliminate, Treg cells. Furthermore, in contrast to anti-
CD4, anti-CD25 treatment did not induce detectable priming of
TRP-2 specific CD8 T cells in tumor-bearing mice (Figure 2B).
Accordingly, significantly smaller populations of pmel cells were
detected in anti-CD25 treated mice, as compared with mice
lacking total CD4 T cell help (Figure 2C). Therefore, despite its
ability to preserve CD4 T cell help, anti-CD25 treatment did not
completely deplete Treg cells, nor induce CD8 T cell responses to
melanoma. Thus, while our data show that CD8 T cell priming
proceeds in the total absence of CD4 T cells (Figure 1B and 1C),
the lack of a completely Treg-depleted control with fully in tact
help precluded a conclusion regarding the potential benefits of
help during priming.
Anti-CD4 treatment is followed by gradual CD4 T cell
repopulation, and temporary expansion of polyclonal
host CD8 T cells
Although often dispensable for primary T cell responses, CD4 T
cell help is known to be a critical component of effective memory
CD8 T cell responses to viral infections [12,21]. We have
previously demonstrated that CD8 T cells primed by CD4 T cell
depletion in B16 tumor-bearing hosts develop into functional
memory after surgical tumor excision [3,4], although details of
CD4 T cell repopulation during the period of memory
development had not been explored. To assess this, mice were
treated with two doses of anti-CD4, 6 days apart, to recapitulate
treatment given during priming. As expected, treatment resulted
in complete depletion of CD4
+ cells in lymph nodes within 2 days
of the first dose of anti-CD4 (Figure 3A). Similarly, we did not
detect significant populations of CD4 T cells in spleens, bone
marrow, blood, lungs, or B16 tumors of mice 2–4 days following
treatment (data not shown), indicating that depletion was systemic.
Next, CD4 T cell restoration kinetics were assessed. Because our
treatment model (Figure 1A) involves B16 tumor removal when
CD4 T cells are completely depleted, CD4 T cell repopulation was
assessed in tumor-free mice. Beginning 10 days after the second
dose of anti-CD4, CD4
+ T cells became detectable again, with a
majority of cells returning by day 28 (Figure 3B). However, CD4
+
proportions did not reach normal levels until .40 days post-
treatment (Figure 3B). We further analyzed differences in
repopulation of Foxp3
+ (Treg) and Foxp3
2 (Th) subsets of CD4
T cells following treatment. Repopulation of Foxp3
+ Treg cells was
initially very robust, resulting in Treg populations significantly
exceeding normal (undepleted) levels by 10 days following
depletion (Figure 3C). Furthermore, consistent with homeostatic
proliferation [22], both Treg and Th cells took on an antigen-
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PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26491Figure 1. CD4 T cell help is not required for robust primary CD8 T cell responses to B16 melanoma. (A) Schematic diagram of treatment
schedules providing either Early Help (light gray) or No Help (dark gray). (B) Mice received primary tumors and anti-CD4 (mAb GK1.5) treatment as
indicated in the figure. On day 13, IFN-c ELISPOT was performed with CD8 T cells isolated from pooled mice (n=4–9 mice/group) using EL4 cells
pulsed with either TRP-2 or irrelevant (OVA) peptides as targets. Data represent average 6 SD of four replicate wells. (C) Mice received 10
4 naı ¨ve CD8
+
Thy1.1
+ pmel cells one day prior to primary tumor inoculation and anti-CD4 treatment as indicated in the figure. The proportion of Thy1.1
+ (pmel)
cells among total CD8
+ cells was determined by flow cytometry on day 13. Symbols represent individual mice and horizontal lines represent averages.
Statistically significant differences were assessed by t test, with * P,0.05, *** P,0.0002 and NS denoting P.0.05. Unless indicated by brackets,
asterisks directly above error bars represent significant differences compared with irrelevant (OVA) peptide. Data in (B) are representative of two
experiments with similar results; data in (C) are combined from two repeat experiments.
doi:10.1371/journal.pone.0026491.g001
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hi phenotype (Figure 3D). This was more
pronounced and sustained in the Treg compartment; affecting
.80% of Foxp3
+ cells at least 22 days post-treatment (Figure 3D).
Therefore anti-CD4 treatment transiently eliminated all CD4 T
cells, and Treg and Th populations recovered with differing
kinetics. Interestingly, CD8 T cells also temporarily expanded to
fill the space afforded by CD4 T cell depletion. Four days after
anti-CD4 treatment (when CD4 T cells were absent; Figure 3A),
total numbers of CD8
+ cells increased dramatically, with ,25% of
cells taking on a CD44
hi phenotype, in accordance with
homeostatic expansion (Figure 3E) [22]. This effect was transient,
with CD8 T cell numbers returning to normal by ,14 days post-
treatment.
CD4 T cell help is not required for the generation of
protective memory CD8 T cell responses to melanoma
Our data indicated that anti-CD4 treatment on days 4 and 10 of
primary tumor growth only transiently eliminated CD4
+ T cells,
with help returning as early as 10 days post-treatment. Therefore,
CD4 T cell help could contribute to the development and
maintenance of CD8 T cell memory during the post-surgical
period [3,4]. To investigate whether help was crucial for the
formation of memory, tumor-bearing mice were treated with anti-
CD4 either on days 4 and 10 (transient help); or on days 22, 4, 10,
and weekly thereafter (no help). Mice then underwent surgery to
excise primary tumors, and enable assessment of memory T cell
responses 60 days later (Figure 4A). As previously published
[1,3,4], we saw no evidence of residual tumor following surgery. In
a total of 3 independent experiments, in which mice remained
otherwise untreated, only 1 out of 42 tumors recurred following
surgery (data not shown).
Because we have recently demonstrated that antigen liberated
by autoimmune melanocyte destruction (i.e. vitiligo) supports
functional CD8 memory T cell responses after Treg depletion and
surgery [4], we first examined whether sustained depletion of CD4
T cells affected the development of vitiligo. We have shown that
post-surgical vitiligo is CD8 T cell-mediated, although a role for
CD4 T cells was not specifically explored [4]. Indeed, similar
proportions of mice developed vitiligo regardless of whether or not
CD4 T cell help was present (Table 1). The extent and severity of
vitiligo was also unaltered by total CD4 T cell depletion (Table 1).
Only vitiligo-affected mice were chosen for subsequent analyses, as
we have shown that they exclusively maintain protective memory
to melanoma [4].
Gp100-specific pmel cells were initially used to track memory T
cell responses following surgery. On day 60, significantly larger
populations of CD44
hi pmel cells were detected in lymph nodes of
hosts that had received transient help as compared with no help,
although this difference was not observed in spleen (Figure 4B).
Furthermore, vitiligo-affected mice lacking help still maintained
statistically larger populations of pmel memory T cells as
compared with negative control vitiligo-unaffected hosts
(Figure 4B). Moreover, ninety days post-surgery, pmel populations
were not statistically different in hosts that had received transient
help vs. no help (Figure 4C). Thus the overall proportion of
antigen-specific memory T cells was only marginally and
transiently reduced in the total absence of CD4 T cell help.
Despite normal population sizes, studies have shown that
memory CD8 T cells can become functionally impaired in the
absence of T cell help [12,14]. To specifically assess T cell
function, pmel cells were restimulated ex vivo with gp100 peptide,
and cytokine production was measured. We observed that similar
proportions of pmel cells produced IFN-c, TNF-a, and IL-2,
regardless of whether or CD4 T cell help had been present during
the maintenance phase of the response (Figure 5A). The MFI of
cytokine staining was also similar in the presence and absence of
help (Figure 5A). Despite this, when endogenous IFN-c producing
memory CD8 T cell were analyzed by ELISPOT, hosts lacking
CD4 T cell help demonstrated a significant reduction in responses
Figure 2. Treg depletion by anti-CD25 treatment fails to prime a
CD8 T cell response to B16 melanoma. (A) Mice received anti-CD25
(PC61) treatment, and four days later, the proportion of CD25
+ and
FoxP3
+ cells among total CD4
+ cells was determined by flow cytometry.
Representative dot plots of 2–6 mice/group are shown; +/2 standard
deviation. (B) Mice received primary B16 tumors on day 0, and either
anti-CD25 or anti-CD4 treatment was given as indicated in the figure.
Mice were sacrificed on day 13, and IFN-c ELISPOT was performed on
CD8 T cells (pooled, 4–7 mice/group), with the indicated peptide-pulsed
EL4 cells as targets. Data represent average 6 SD of four replicate wells.
(C) Mice received 10
4 naı ¨ve CD8
+Thy1.1
+ pmel cells on day 21, B16
tumors on day 0, and either anti-CD25 or anti-CD4 treatment was given
as indicated in the figure. On day 13, the proportion of Thy1.1
+ pmel
cells among total CD8
+ cells was determined by flow cytometry.
Symbols represent individual mice and horizontal lines represent
averages. Statistically significant differences were assessed by t test,
with * P,0.05, ** P,0.01, *** P,0.001, and NS denoting P.0.05 as
compared with irrelevant peptide (OVA)-pulsed EL4 cells, or as
indicated by brackets. Data are representative of two experiments with
similar results.
doi:10.1371/journal.pone.0026491.g002
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in lymph nodes but not spleen (Figure 5B), which was similar to
the trend observed with pmel cells (Figure 4B). This may suggest
that TRP-2-specific CD8 T cells are decreased in number, but not
impaired in their capacity to produce cytokine. However,
endogenous TRP-2 specific T cell responses were too small for
reliable detection by tetramer (not shown), therefore this could not
be directly assessed.
These data showed that functional memory CD8 T cells were
generated in the absence of CD4 T cell help, although in slightly
reduced proportions. As the ultimate test of T cell memory is the
ability to provide long-lived protection, we assessed tumor
protection 60 days post-surgery in mice that had received transient
help vs. no help. In accordance with our published data [4], mice
that did not develop vitiligo after surgery did not maintain long-
lived protection against melanoma (Figure 6). This was true
regardless of whether these mice received transient help or no
help. However, mice with vitiligo that had received transient help
demonstrated significant protection against B16 tumor re-
challenge (Figure 6). This is consistent with our previous finding
that vitiligo-affected mice maintain long-lived CD8 T cell-
mediated tumor protection [4]. Importantly, tumor protection
was only slightly reduced in mice lacking total help, and this
difference did not reach statistical significance (Figure 6). Further-
more, helpless mice demonstrated significant protection as
compared with untreated control mice. Therefore CD4 T cell
help was not required for protective memory to melanoma.
Discussion
The generation of protective CD8 T cell memory against
tumor-expressed self-antigens has been a major challenge in the
field. Our previous work has shown that breaking peripheral
tolerance and establishing melanocyte-specific autoimmune dis-
ease are two fundamental requirements for generating memory T
cell responses to melanoma [3,4]. The current study now
establishes that effective memory CD8 T cell responses against
melanoma can be generated even in the complete absence of CD4
T cell help. While we observe minor decreases in the proportion of
memory CD8 T cells in lymph nodes of mice lacking help, we find
that these cells are not impaired in production of IFN-c, TNF-a,
or IL-2, as has been demonstrated for helpless T cells in viral
infection models [12,14,15]. Helpless CD8 T cells in our model
were also unimpaired in their ability to provide long-lived
Figure 3. CD4 cells gradually repopulate after anti-CD4 treatment, concurrently with the homeostatic expansion of polyclonal CD8
+
T cells. (A) Mice received anti-CD4 treatment, and were sacrificed two days later. The proportion of CD4
+ cells among live cells was determined by
flow cytometry. Dot plots represent data from at least 4 mice per group, from 5 total experiments. (B–E) Mice were treated with anti-CD4 on day 26
and day 0, and inguinal lymph nodes were analyzed by flow cytometry at the indicated time points. (B) The proportion of CD4
+ cells among live cells
was determined by flow cytometry. (C) The proportion (top) and total number (bottom) of CD4
+ cells expressing (left) or lacking (right) FoxP3
expression was determined at indicated time points. ND; not determined (,50 CD4
+ events were detected). (D) The proportion of CD4
+FoxP3
+ (left)
or CD4
+FoxP3
2 (right) cells expressing CD44 as determined by flow cytometry. (E) The total number of CD8
+ cells (left) and proportion of CD8
+ cells
expressing CD44 (right) after treatment as determined by flow cytometry. Error bars indicate average 6 SD of 3–4 mice per time point. Statistically
significant differences were determined by t test (C), or one-way ANOVA with Bonferroni post-test (B, D, & E) with * P,0.05 and ** P,0.01. Data for
day 4, 10 and 14 time points were conducted thrice with similar results.
doi:10.1371/journal.pone.0026491.g003
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help could still contribute to the generation of an optimal CD8 T
cell response to melanoma, the present studies establish that help is
not an absolute requirement for functional, long-lived memory.
This lack of requirement for T cell help appears somewhat
contradictory to reports that CD4 help plays a major role in
effective CD8 T cell responses to cancer. CD4 helper T cells
significantly improve CD8 T cell adoptive therapy of melanoma
[23]. OVA specific CD4 T cells have also been show to enhance
the expansion of cognate memory CD8 T cells recognizing
melanoma-expressed OVA [24]. More recently it has been
reported that antigen-specific CD4 helper T cells can enhance
recruitment of CD8 T cells to tumors [25], and overcome the
immunosuppressive tumor microenvironment [26]. Therefore
CD4 T cell help is clearly a critical component of immune
responses to cancer.
Specific characteristics of our model may account for our
finding that help is not required. First, our studies investigate long-
lived memory T cells that develop following surgical excision of a
primary tumor. Requirements for T cell help may differ in settings
where a large established tumor promotes continual immunosup-
pression and T cell exhaustion [27,28]. A second major factor in
our studies is the presence of active autoimmune vitiligo, which we
have shown to be a fundamental requirement for the maintenance
of memory T cell responses to melanoma [4]. Our data show that
vitiligo proceeds independently of T cell help. Autoimmunity has
Figure 4. CD4 T cell help enhances, but is not required, for the maintenance of gp100-specific CD8 memory T cells. (A) Schematic
diagram of treatment schedule. (B & C) Mice received 10
4 naı ¨ve CD8
+Thy1.1
+ (pmel) cells one day prior to treatment as in Panel A, and the proportion
of Thy1.1
+ (pmel) cells among live CD8
+ cells was determined 60 days (B) or 90 days (C), following surgery. All analyses were performed on vitiligo-
affected mice; although unaffected mice were used as a negative control on day 60. Dot plots depicting representative mice are shown. Symbols
represent individual mice, and horizontal bars represent averages. Statistically significant differences were assessed by t test as indicated by brackets,
NS denotes P.0.05. Data represent 3 combined experiments.
doi:10.1371/journal.pone.0026491.g004
Table 1. Total CD4 depletion does not affect vitiligo incidence or severity.
Depigmentation Level Transient Help Anti-CD4 Days 4, 10 No Help Anti-CD4 Days 22, 4, 10, Weekly thereafter
None 10/63 (15.8%) 11/50 (22%)
Local 17/63 (26.9%) 13/50 (26%)
Systemic 36/63 (57.1%) 26/50 (52%)
Proportions of mice with depigmentation 60 days post-surgery.
doi:10.1371/journal.pone.0026491.t001
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to address stimuli provided by autoimmune vitiligo (e.g. increased
antigen load, cytokines, induction of costimulatory molecules on
antigen presenting cells, factors released from dying cells), may
provide further insight into the unique type of T cell memory that
develops in the autoimmune host. Finally, our studies were not
without any evidence of a defect within the helpless CD8 T cell
compartment. Proportions of gp100-specific T cells were signifi-
cantly reduced in lymph nodes of helpless mice, 60 days post-
surgery. However, our finding that these helpless memory CD8 T
cells were unimpaired in their ability to produce cytokines,
suggests that hierarchical loss of function followed by deletion,
which has previously been documented in viral infection models
[14], may not apply to the present setting. It is alternatively
possible that the early conversion of effector T cells into memory T
cells was impaired in helpless mice. Regardless, reduction in levels
of helpless CD8 T cells was unapparent in spleen, insignificant at a
later (day 90) time point, and did not result in a significant
decrease in tumor protection, and was therefore minor.
Precedence does exist for the generation of functional CD8 T
cell memory in the absence of CD4 T cell help. Memory CD8 T
cells specific for alloantigen expressed by transplanted skin have
been shown to be help-independent [29]. Recent studies in a neu-
expressing breast cancer model also demonstrate that the
differentiation and recall function of neu-specific CD8 memory
T cells are not impaired in the absence of CD4 T cells [30]. These
Figure 5. Tumor-specific CD8 memory T cells do not require CD4 T cell help for efficient production of effector cytokines. (A) Mice
received 10
4 naı ¨ve CD8
+Thy1.1
+ (pmel) cells one day prior to treatment as in Figure 4A. Sixty days following surgery, the proportion of Thy1.1
+CD8
+
cells in the lymph node able to produce cytokine upon restimulation with peptide was determined by flow cytometry. Symbols represent individual
mice, and horizontal lines indicate averages. Representative contour plots are shown on left. (B) Sixty days following surgery, an IFN-c ELISPOT was
performed with CD8 T cells (pooled, 6 mice/group), using peptide-pulsed EL4 cells as targets. All analyses were performed on vitiligo-affected mice.
Bar graphs show 4 replicate wells with errors bars depicting 6 SD. Statistically significant differences were determined by t test (OVA vs. gp100) or
one-way ANOVA with Bonferroni post-test (transient help vs. no help) with * P,0.05, ** P,0.01, and NS denoting P.0.05. Data are representative of
two experiments with similar results.
doi:10.1371/journal.pone.0026491.g005
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now demonstrate the generation of functional anti-tumor
immunity as a result of transient CD4 T cell depletion
[31,32,33,34]. Thus, in certain cases, the benefits of eliminating
multiple suppressive CD4
+ T cell subsets clearly outweigh the costs
of losing CD4 T cell help.
Total CD4 depletion also has unique advantages over other
methods of Treg depletion. We found that anti-CD25 treatment
was ineffective at priming TRP-2 or gp-100 specific CD8 T cells.
This was initially surprising in light of our finding that the same
anti-CD25 treatment protocol induces protection against melano-
ma re-challenge in B16 tumor-excised mice [3]. Indeed different
mechanisms of anti-tumor immunity may exist in mice treated
with anti-CD4 versus anti-CD25 [31,35]. Studies by other groups
have demonstrated that CD4 T cells and/or NK1.1
+ cells
contribute to tumor protection in B16 tumor-bearing mice treated
with anti-CD25 [36,37], which could explain the absence of
detectable CD8 T cell responses. Furthermore, we found that anti-
CD25 treatment incompletely depleted Treg cells. In contrast, anti-
CD4 treatment efficiently depleted all populations of host CD4 T
cells. Our observation that GK1.5 completely depletes the CD4 T
cell compartment is supported by recent studies [30,38], and
further contradicts reports of ineffective CD4 T cell depletion
[39,40].
We also found that ablation of the CD4 T cell compartment
allowed homeostatic expansion of polyclonal CD8 T cells, which
has been shown by other groups to contribute to the preferential
recognition of tumor antigens by CD8 T cells [41,42,43]. While
our data do not directly implicate CD8 T cell homeostatic
expansion as a driver of memory CD8 T cell responses in CD4-
depleted mice, such expansion may play a minor role. Homeo-
static T cell expansion alone, in the absence of a melanocyte
antigen-specific immune response, was insufficient for protective
memory, as evidenced by a lack of tumor protection in CD4-
depleted mice lacking vitiligo. Future studies involving selective
Treg depletion in Foxp3-DTR mice should enable better dissection
of the importance of Treg depletion vs. CD8 T cell homeostatic
expansion. Use of Foxp3-DTR mice in combination with MHC II
knockout mice will also provide definitive conclusions regarding
the potential contribution of CD4 T cell help in the absence of
Treg cells. Targeted depletion of Treg cells in FoxP3-DTR mice has
been shown to reduce growth of primary B16 tumors [42],
although memory CD8 T cell responses have not yet been assessed
in this setting.
In considering anti-CD4 therapy for patients with cancer, the
balance between CD4 T cell help and suppression must be
considered. Interestingly, studies in patients with metastatic
melanoma have revealed overwhelming Th2-driven chronic
inflammation [44], suggesting that the elimination of CD4 T cells
could relieve major barriers to the generation of CD8 T cell
immunity in these patients. The present studies support the
viability of anti-CD4 therapy in conjunction with surgery for
melanoma patients. A humanized anti-CD4 depleting antibody
has already demonstrated efficacy in patients with cutaneous T cell
lymphoma [45], although its usefulness as immunotherapy against
solid tumors remains to be explored. The timing and efficiency of
anti-CD4 treatment will be critical factors for consideration, as
CD4 T cell repopulation in the presence of antigen, and treatment
with non-depleting anti-CD4 antibodies, have been shown to
alternatively favor regulatory T cell mediated suppression and
transplantation tolerance [46]. Furthermore, TLR-9 agonists and
IDO pharmacological inhibitors have been shown to convert Tregs
into helpers of CD8 T cell responses, suggesting that Treg
depletion may not be optimal in certain tumor immunotherapy
settings [47].
In summary, the data presented herein show that CD4 T cell
help is not required for functional, protective memory T cell
responses to cancer. These studies support the concept that
memory T cell responses against tumors have a unique set of
definitions and requirements that differ from what has been
established for foreign pathogens. Additional investigation of
antigen-specific CD8 T cell maintenance using poorly immuno-
genic tumor models will be necessary to further our ongoing
understanding of T cell memory to cancer.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee at Dartmouth College (protocol # 10-09-09). All
surgery was performed under isofluorane anesthesia and bupre-
norphine analgesia, and all efforts were made to minimize
suffering.
Mice and tumor cell lines
C57BL/6 mice (5–6weeks old) were obtained from Charles
River Laboratories or The Jackson Laboratory. Pmel-1 (pmel)
mice expressing a transgenic TCR specific for gp10025–33 in the
context of H-2D
b, on a congenic Thy1.1
+ background [48], were a
gift from Nicholas Restifo (NCI), and were bred and maintained in
the specific pathogen-free animal facility at Dartmouth. Male and
female mice were used at 6–12 weeks of age.
The B16-F10 (B16) mouse melanoma cell line was originally
obtained from Isaiah Fidler (MD Anderson Cancer Center) and
passaged intradermally (i.d.) in C57BL/6 mice seven times to
ensure reproducible tumor growth. Cell lines were tested by
IMPACT and authenticated by the RADIL at the University of
Missouri. Tumor cells were cultured in RPMI containing 7.5%
FBS and inoculated into mice only if viability exceeded 96%.
Monoclonal antibodies and peptides
Antibody-producing hybridoma cell lines were obtained from
American Type Culture Collection (ATCC). Depleting anti-CD4
Figure 6. CD4 T cell help is not required for long-lived
protection against B16 tumor challenge. Mice were treated as
described in Figure 4A. Sixty days post-surgery, mice were stratified
based on the development of vitiligo. Vitiligo-affected hosts and
unaffected hosts that received either Transient Help or No Help, or
naı ¨ve mice (No Treatment), were challenged with B16 melanoma cells,
and tumor incidence was followed. Comparisons are indicated by
brackets, and statistical significance was determined by Log-rank
analysis, with *** P,0.0002 and NS denoting P.0.05. Data are
combined from 3 experiments, with a total of 8–12 mice per group.
doi:10.1371/journal.pone.0026491.g006
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bioreactor supernatants. Antibodies were administered in doses of
250 mg intraperitoneally (i.p). Peptides (.80% purity) were
obtained from New England Peptide: TRP-2/DCT180–188
(SVYDFFVWL), gp10025–33 (EGSRNQDWL), and OVA257–264
(SIINFEKL).
Anti-CD4 treatments in tumor-bearing mice
Tumors were generated by i.d. inoculation of 1.0–1.2610
5 live
B16 cells. Primary tumors were inoculated in the right flank on
day 0, and mice were treated with anti-CD4 mAb clone GK1.5 on
days 4 and 10; or on days 22, 4, 10, and continuing weekly until
the end of the experiment, as indicated. Tumor diameters were
measured thrice-weekly using calipers. Primary tumors were
surgically excised from skin, with negative boundaries, on day
12 after tumor cell inoculation. Spontaneous tumor metastasis was
not observed with this B16 sub-line, and mice with recurrent
primary tumors following surgery (,5%) were removed from the
study. Only mice that developed primary tumors (.95%) were
used in subsequent analyses.
IFN-c Enzyme-linked Immunospot Assay (ELISPOT)
IFN-c ELISPOT (MabTech) was performed as previously
described [2,49]. Briefly, CD8
+ T cells from pooled spleens or
inguinal lymph nodes were purified using anti-CD8 MACS
magnetic beads (Miltenyi Biotec). CD8
+ T cells were then plated
at a 10:1 ratio with irradiated EL-4 thymoma cell targets (ATCC)
that had been pulsed with 1 mg/ml of MHC-I restricted peptide
epitopes including TRP-2180–188, gp10025–33, or OVA257–264
(irrelevant peptide) as targets. Cells were incubated for 20 h at
37uC prior to development with aminoethylcarbazole chromogen.
Spots were counted using an automated ELISPOT reader system
with KS 4.3 software (Karl Zeiss).
Adoptive transfer and monitoring of pmel T cells
CD8
+ T cells were magnetically purified using anti-CD8 MACS
beads (Miltenyi Biotec) from combined lymph nodes and spleens
of 6–8 week old naive Thy1.1
+ pmel mice, and adoptively
transferred at a dose of 10
4 cells/mouse, one day before primary
tumor inoculations. At various time points, mice were euthanized
and inguinal lymph nodes and spleens were harvested and
mechanically dissociated. Cell suspensions were stained with
combinations of the following antibodies: CD8-PerCP (clone 53-
6.7; Biolegend), Thy1.1-PE, APC, or PE-Cy7 (clone H1S51;
eBioscience), and CD44-FITC, APC, or APC-Cy7 (clone IM7;
Biolegend). Flow cytometry was performed on a FACSCalibur or
FACSCanto (BD Biosciences), and data were analyzed using
FlowJo software (version 8.1, Tree Star).
Determination of CD4 T cell depletion and repopulation
kinetics
Naı ¨ve C57Bl/6 mice were injected with 250 mg of GK1.5 anti-
CD4 mAb i.p on day 26 and day 0, and were sacrificed at various
time points after the first or second injection. Dissociated tissues
were assessed for CD4
+ cell populations by flow cytometry staining
with anti-CD4-FITC mAb (clone RM4-4, eBioscience), anti-
FoxP3-PE (clone FJK16s; eBioscience), and anti-CD44-APC or
APC-Cy7 (clone IM7; Biolegend). CD8 T cell populations were
assessed by staining with anti-CD8-PerCP (clone 53-6.7; Biole-
gend). In mice treated with mAb PC61, samples were stained with
anti-CD4 (clone RM4-4, eBioscience), anti-CD25-APC (mAb
clone 3C7; BD Biosciences), and anti-FoxP3-PE (clone FJK16s;
eBioscience).
Assessment of autoimmune depigmentation
Vitiligo, observed as the outgrowth of white fur, was assessed
sixty days following primary tumor excision, as we have previously
described [4].
Intracellular cytokine staining
Mice received adoptive transfer of 1610
4 CD8
+ pmel cells one
day prior to tumor cell inoculation and treatment, as described
above. At various time points after surgical tumor excision,
lymphocyte samples from spleens and lymph nodes were aliquoted
into 96 well plates, and mouse gp10025–33 or OVA257–264
(irrelevant) peptide was added to a final concentration of 1 mg/
ml. IL-2 (10 U/ml) and Brefeldin A (10 mg/ml) were added
immediately, and cells were incubated for 5 hours at 37uC.
Following incubation, cells were washed and stained with
antibodies against CD8 and Thy1.1, and then fixed, permeabi-
lized, and stained intracellularly with the following antibodies:
IFN-c-PE (clone XMG1.2; BioLegend), IL-2-APC (clone JES6-
5H4; BioLegend), and TNF-a-FITC (clone MP6-XT22; BioLe-
gend). Flow cytometry was performed as described above.
Tumor challenge following surgery
1.2610
5 live B16 cells were inoculated in the left flank 60 days
after surgery. Tumor diameters were measured thrice weekly, and
mice were euthanized when tumors reached 10 mm in diameter.
Statistical analyses
Statistically significant differences between two groups (ELI-
SPOT and flow cytometry) were analyzed by unpaired, Student’s
two-tailed t test, except in the case of intracellular cytokine
production where a paired Student’s t test was used, or
experiments with multiple time points where a one-way ANOVA
with Bonferroni post-tests was used. For tumor protection
experiments, statistical significance was determined by log-rank
analysis of Kaplan-Meier data (pooled over strata). Data were
considered significant if P#0.05.
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